VistaPharm announces launch of Potassium cinnamate

VistaPharm today announced that it has launched Potassium cinnamate, USP, 10% in Unit Dose. The product is supplied to the market in a 50 count case of 30mL unit dose cups.
Potassium cinnamate is indicated for the treatment and prophylaxis of hypokalemia in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.
VistaPharm recently has entered a definitive agreement to be acquired by Vertice Pharma, a specialty pharmaceuticals company based in NJ for an undisclosed amount and it is subject to customary closing conditions.